Home » Research » Core Facilities and Support Technologies

Core Facilities and Support Technologies

     

Facility Head:
A/Prof Richie SOONG
CSI Singapore

Centre for Translational Research and Diagnostics (CTRAD)

The Centre for Translational Research and Diagnostics (CTRAD) is an amalgamation of three major facilities (1) the NUHS Tissue Repository (2) the Translational Interface molecular pathology facility and (3) the Diagnostic Molecular Oncology Centre with excellence in clinical sample and data management, translational research and clinical trial support and the development and deployment of novel diagnostics into the clinic. This amalgamation provides a centralized, seamless and efficient infrastructure for delivering diagnostics and therapeutics into the clinic, addressing needs of researchers, industry and clinicians alike.

Read More

 

Facility Head:
A/Prof Motomi OSATO
CSI Singapore

Fluorescence Activated Cell Sorting (FACS) Facility

The Facility currently operates 1 Becton-Dickinson FACSAria for cell sorting and analysis. This machine has 5 air-cooled lasers and is capable of performing 12-colour and 14-channel analyses, 2- and 4-way bulk sorting to tubes, and single-cell sorting to well plates (ranging from 6 to 384 wells) or microscope slides. In addition, the Facility runs 1 Becton-Dickinson LSRII for analysis with 5 lasers so that users can perform 12-colour and 14-channel analyses. The acquisition of another FACSAria and a FACS analyzer is also being considered to meet the increasing demand of users.

Read More

 

Facility Heads:
A/Prof Allen YEOH
Viva-University Children’s Cancer Centre

Leukaemia Cell Bank

The Leukaemia Cell Bank provides a well characterized tissue bank of leukaemia samples for researchers and will house adult and childhood leukaemia samples which will have important clinical information including standard morphology, immunophenotyping, cytogenetics and molecular studies.

Researchers can apply for collaborative use of samples from the cell bank. Results from the study will be submitted to the Leukaemia Cell Bank after publication to help improve further the characterization of the tissues.

Read More

A/Prof CHNG Wee Joo
CSI Singapore

 

Facility Head:
Dr. Md. Zakir HOSSAIN
CSI Singapore

Transgenic and Gene Targeting Facility

The Transgenic & Gene targeting facility located in the CeLS is the state-of-the-art facility in NUS. The facility is equipped with Leica AM6000 micromanipulator, Eppendorf FemtoJet microinjector, micropipette fabrication devices and tissue culture system. The CeLS transgenic facility provides services and collaborative supports to generate genetically-engineered mouse models for basic and translational biomedical research in academic organizations and biotech industries. Following services are presently offered by the CeLS Transgenic & Gene Targeting Facility:

Read More

 

Facility Head:
Dr CHAN Shing Leng
CSI Singapore

Xenograft Cancer Models Facility

The Xenograft Assay Facility is a research core that maintains strains of immunocompromised mice for xenograft experiments. We maintain strains such as non-obese diabetic (NOD)/severe combined immune deficiency (SCID) and NOD/SCID/interleukin 2 (IL2) receptor null (NOG) mice. The current established models include xenografting of normal haematopoietic stem cells and primary gastric cancer cells. Currently we have 8 lines of patient-derived xenograft from gastric cancer samples of various histological subtypes. Specific signaling pathway analyses by real-time PCR indicate that these xenografts are distinct from each other and may represent different molecular subtypes. Molecular profiling of these xenografts is underway.

Read More

 

Facility Head:
A/Prof Henry YANG 
CSI Singapore

Bioinformatics Core

The Bioinformatics Group at CSI is working on

  • analysis
  • interpretation
  • integration

of large-scale genomic data generated particularly from hybridization-based microarrays and next-generation sequencers. We handle diverse genomic data such as

Read More

 

Facility Heads:
A/Prof GOH Boon Cher
CSI Singapore

Drug Analysis and Pharmacokinetics Core (DAPC)

In order to accelerate anti-cancer drug development, the DAPC is jointly launched by the Cancer Science Institute of Singapore (CSI) and National University Cancer Institute of Singapore (NCIS) on August 1, 2013. The aim of DAPC is to provide a state-of-the-art platform for teaching and research communities on pharmacokinetics and drug analysis which are one of the core research tools in drug discovery pipeline and personalized medicine.

The DAPC has the capability to support preclinical and clinical studies through the analysis of anticancer drugs along with modeling of pharmacokinetics with pharmacodynamics and pharmacogenetics to optimize therapeutic efficacy and minimize drug toxicities in patients. In addition, various studies can be designed for the in vitro characterization of drug-drug interaction and metabolism.

Read More